Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for asthma
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Fasenra - benralizumab - Asthma, severe eosinophilic benralizumab | CADTH.ca Find the information you need benralizumab benralizumab Last Updated: January 7, 2019 Result type: Reports Project Number: SR0561-000 Product Line: Generic Name: benralizumab Brand Name: Fasenra Manufacturer: AstraZeneca Canada Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria 1 : For add-on maintenance treatment of adult patients with severe eosinophilic asthma who (...) are inadequately controlled with high-dose inhaled corticosteroids (ICS) and one or more additional asthma controller(s) (e.g., LABA), if one of the following clinical criteria are met: 1. Blood eosinophil count of 300 cells/L AND have experienced two or more clinically significant asthma exacerbations in the past 12 months, or 2. Blood eosinophil count of 150 cells/L and are treated chronically with oral corticosteroids (OCS). Submission Type: New Project Status: Active Biosimilar: No Date Recommendation
Nucala - mepolizumab - Asthma, severe eosinophilic mepolizumab | CADTH.ca Find the information you need mepolizumab mepolizumab Last Updated: April 23, 2019 Result type: Reports Project Number: SF0593-000 Product Line: Generic Name: mepolizumab Brand Name: Nucala Manufacturer: GlaxoSmithKline Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria 1 : Not applicable. Submission Type: Request For Advice Project Status: Complete Biosimilar: No Companion (...) Asthma Canada and The Ontario Lung Association Patient input summary sent for review to patient input groups December 17, 2018 Patient group comments on input summary closed December 20, 2018 Clarification: - Patient input summary feedback received Request for Advice received October 24, 2018 Manufacturer informed of request for advice October 24, 2018 Manufacturer information or comments due November 07, 2018 Request for Advice initiated October 29, 2018 Draft CDR Request for Advice report sent
Fasenra - benralizumab - Asthma, severe eosinophilic benralizumab | CADTH.ca Find the information you need benralizumab benralizumab Last Updated: April 23, 2019 Result type: Reports Project Number: SF0592-000 Product Line: Generic Name: benralizumab Brand Name: Fasenra Manufacturer: AstraZeneca Canada Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria 1 : Not applicable. Submission Type: Request For Advice Project Status: Complete Biosimilar (...) received from Asthma Canada and The Ontario Lung Association Patient input summary sent for review to patient input groups December 17, 2018 Patient group comments on input summary closed December 20, 2018 Clarification: - Patient input summary feedback received Request for Advice received October 24, 2018 Manufacturer informed of request for advice October 24, 2018 Manufacturer information or comments due November 07, 2018 Request for Advice initiated October 29, 2018 Draft CDR Request for Advice
Cinqair - reslizumab - Asthma, eosinophilic reslizumab | CADTH.ca Find the information you need reslizumab reslizumab Last Updated: April 23, 2019 Result type: Reports Project Number: SF0591-000 Product Line: Generic Name: reslizumab Brand Name: Cinqair Manufacturer: TEVA Canada Innovation Indications: Asthma, eosinophilic Manufacturer Requested Reimbursement Criteria 1 : Not applicable Submission Type: Request For Advice Project Status: Complete Biosimilar: No Date Recommendation Issued: March (...) 27, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable. Key Milestones 1 Call for patient input posted October 24, 2018 Patient group input closed December 12, 2018 Clarification: - Patient input submission received from Asthma Canada and The Ontario Lung
Breaking through Restricting Bottleneck for Better Asthma Control 29340274 2019 01 28 2450-131X 5 4 2017 Dec Journal of translational internal medicine J Transl Int Med Breaking through Restricting Bottleneck for Better Asthma Control. 192-193 10.1515/jtim-2017-0032 Zhu Ding D Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. Zhang Chao C Department (...) Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. eng Journal Article 2017 12 29 Poland J Transl Int Med 101673826 2224-4018 Conflict of Interest: None declared. 2018 1 18 6 0 2018 1 18 6 0 2018 1 18 6 1 epublish 29340274 10.1515/jtim-2017-0032 jtim-2017-0032 PMC5767707 Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24 19815809 J Asthma. 2016;53(1):94-100 26383773 Respir Med. 2006 Jul;100(7):1139-51 16713224 J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):293-299
Evaluation of anxiety and depression in mothers of children with asthmaAsthma is the most common chronic disease in childhood. Parents have an important role in managing asthma in children. Studies have shown a higher degree of depression and anxiety and lower family performance in mothers of asthmatic children in comparison with the control group.The aim of this study was to evaluate the parenting styles and also depression, anxiety and stress parameters in mothers of children (...) (DASS). The mothers were also asked to fill a strengths and difficulties questionnaire (SDQ) for their children. Furthermore, parenting styles in the case group were compared to mothers of children without asthma as the control group. The data were then analyzed by SPSS 11.5, using Chi-square, ANOVA, and independent-samples t-test.The results of this study showed that 21 mothers (74.6%) were normal, but 12 mothers (26.7%) had a mild -, 9 (20%) a moderate - and 3 (6.7%) a severe degree of abnormality
Asthma. Asthma-one of the most common chronic, non-communicable diseases in children and adults-is characterised by variable respiratory symptoms and variable airflow limitation. Asthma is a consequence of complex gene-environment interactions, with heterogeneity in clinical presentation and the type and intensity of airway inflammation and remodelling. The goal of asthma treatment is to achieve good asthma control-ie, to minimise symptom burden and risk of exacerbations. Anti-inflammatory (...) and bronchodilator treatments are the mainstay of asthma therapy and are used in a stepwise approach. Pharmacological treatment is based on a cycle of assessment and re-evaluation of symptom control, risk factors, comorbidities, side-effects, and patient satisfaction by means of shared decisions. Asthma is classed as severe when requiring high-intensity treatment to keep it under control, or if it remains uncontrolled despite treatment. New biological therapies for treatment of severe asthma, together
Stormy weather: a retrospective analysis of demand for emergency medical services during epidemic thunderstorm asthma. To describe the demand for emergency medical assistance during the largest outbreak of thunderstorm asthma reported globally, which occurred on 21 November 2016.A time series analysis was conducted of emergency medical service caseload between 1 January 2015 and 31 December 2016. Demand during the thunderstorm asthma event was compared to historical trends for the overall (...) November, compared with a daily average of 52 during the historical period. After adjustment for temporal trends, thunderstorm asthma was associated with a 42% (95% confidence interval 40% to 44%) increase in overall caseload for the emergency medical service and a 432% increase in emergency medical attendances for acute respiratory distress symptoms. Emergency transports to hospital increased by 17% (16% to 19%) and time critical referrals from general practitioners increased by 47% (21% to 80
Breathing training for dysfunctional breathing in asthma: taking a multidimensional approach Various breathing training programmes may be helpful for adults with asthma. The main therapeutic aim for many of these programmes is the correction of dysfunctional breathing. Dysfunctional breathing can be viewed practically as a multidimensional entity with the three key dimensions being biochemical, biomechanical and psychophysiological. The objectives of this review are to explore how each (...) of these dimensions might impact on asthma sufferers, to review how various breathing therapy protocols target these dimensions and to determine if there is evidence suggesting how breathing therapy protocols might be optimised. Databases and reference lists of articles were searched for peer-reviewed English language studies that discussed asthma or dysfunctional breathing and various breathing therapies. Biochemical, biomechanical and psychophysiological aspects of dysfunctional breathing can all potentially
Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Comparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma eComparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00005-I (...) and safety of bronchial thermoplasty (BT), a procedure that uses heat to remove muscle tissue from the airways of adults with moderate to severe asthma. BT is usually given as three treatments 3 weeks apart. Key Messages • BT along with standard medical management, compared to medical management alone, may improve asthma control and quality of life, but evidence is insufficient to determine impact on asthma exacerbations. • BT along with standard medical management, compared to a similar procedure
International Variation in Asthma and Bronchiolitis Guidelines Guideline recommendations for the same clinical condition may vary. The purpose of this study was to determine the degree of agreement among comparable asthma and bronchiolitis treatment recommendations from guidelines.National and international guidelines were searched by using guideline databases (eg, National Guidelines Clearinghouse: December 16-17, 2014, and January 9, 2015). Guideline recommendations were categorized as (1 (...) ) recommend, (2) optionally recommend, (3) abstain from recommending, (4) recommend against a treatment, and (5) not addressed by the guideline. The degree of agreement between recommendations was evaluated by using an unweighted and weighted κ score. Pairwise comparisons of the guidelines were evaluated similarly.There were 7 guidelines for asthma and 4 guidelines for bronchiolitis. For asthma, there were 166 recommendation topics, with 69 recommendation topics given in ≥2 guidelines. For bronchiolitis
A virtual asthma clinic for children: fewer routine outpatient visits, same asthma control eHealth is an appealing medium to improve healthcare and its value (in addition to standard care) has been assessed in previous studies. We aimed to assess whether an eHealth intervention could improve asthma control while reducing 50% of routine outpatient visits.In a multicentre, randomised controlled trial with a 16-month follow-up, asthmatic children (6-16 years) treated in eight Dutch hospitals were (...) randomised to usual care (4-monthly outpatient visits) and online care using a virtual asthma clinic (VAC) (8-monthly outpatient visits with monthly web-based monitoring). Outcome measures were the number of symptom-free days in the last 4 weeks of the study, asthma control, forced expiratory volume in 1 s, exhaled nitric oxide fraction, asthma exacerbations, unscheduled outpatient visits, hospital admissions, daily dose of inhaled corticosteroids and courses of systemic corticosteroids.We included 210
Inhaled magnesium sulfate in the treatment of acute asthma. Asthma exacerbations can be frequent and range in severity from mild to life-threatening. The use of magnesium sulfate (MgSO₄) is one of numerous treatment options available during acute exacerbations. While the efficacy of intravenous MgSO₄ has been demonstrated, the role of inhaled MgSO₄ is less clear.To determine the efficacy and safety of inhaled MgSO₄ administered in acute asthma.to quantify the effects of inhaled MgSO₄ I (...) ) in addition to combination treatment with inhaled β₂-agonist and ipratropium bromide; ii) in addition to inhaled β₂-agonist; and iii) in comparison to inhaled β₂-agonist.We identified randomised controlled trials (RCTs) from the Cochrane Airways Group register of trials and online trials registries in September 2017. We supplemented these with searches of the reference lists of published studies and by contact with trialists.RCTs including adults or children with acute asthma were eligible for inclusion
Exemplar clinical pathways for a stratified approach to severe asthma The Academy of Medical Sciences 4 ? ? ? ? ? ? ? The Academy of Medical Sciences 5 The Academy of Medical Sciences 6 The Academy of Medical Sciences 7 Introduction to a stratified approach ? ? ? ? The Academy of Medical Sciences 8 The Academy of Medical Sciences 9 ? ? ? The Academy of Medical Sciences 10 The Academy of Medical Sciences 11 The Academy of Medical Sciences 12 The Academy of Medical Sciences 13 Adopting
Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness | CADTH.ca Find the information you need Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Published on: October 31, 2017 Project Number: RA0937-000 Product Line: Research Type: Devices and Systems Report
Why and how to step down chronic asthma drugs. Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials (...) trials support an increased risk of asthma exacerbation for patients who completely stop taking inhaled corticosteroid or long acting bronchodilator. Strategies to implement step-down in practice include the use of risk prediction as well as tools to support shared decision making and communication about risk between clinicians and patients.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights
Caspase-1 deficiency reduces eosinophilia and interleukin-33 in an asthma exacerbation model Rhinovirus infections are common triggers of asthma exacerbations. Viruses can activate the inflammasome, resulting in processing and activation of caspase-1. This recruitment triggers production of interleukin (IL)-1β and IL-18, which have been implicated in asthma. Elucidating the involvement of the inflammasome and its compartments, such as caspase-1, in asthma exacerbations is warranted. Gene (...) after rhinoviral infection exclusively in bronchial epithelial cells from asthmatics. In a translational mouse model of asthma exacerbation effects of caspase-1 on airway inflammation and Th2-upstream cytokines were explored. Caspase-1 deficient mice exhibited no alterations of general lung inflammatory parameters, but showed markedly reduced eosinophilia. Furthermore, the Th2-upstream cytokines IL-33, TSLP and IL-25 were reduced at exacerbation in mice lacking caspase-1. Rhinovirus infection